cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 5 Documents
 1 
Search results for , issue "Vol 11, No 4 (2017): October- December 2017" : 5 Documents clear
Tingkat Depresi pada Pasien Kanker di RSUP Dr. Sardjito, Yogyakarta, dan RSUD Prof. Dr. Margono Soekarjo, Purwokerto: Pilot Study WIDIYONO S; SRI SETIYARINI; CHRISTANTIE EFFENDY
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (365.844 KB) | DOI: 10.33371/ijoc.v11i4.535

Abstract

Depression is psychological distress often occurred on cancer patient. Depression can increase perception about pain, reducing drug efficacy and longer length of stay at hospital. The objective of this study was to describe the condition of cancer patients depression who undergoing treatment at RSUP Dr. Sardjito Yogyakarta and RSUD Prof. Dr. Margono Soekarjo Purwokerto. This was a descriptive study using a cross sectional design and a pilot study. Subject were taken using non probability with purposive sampling technique. Beck Depression Inventory (BDI) was employed for selection purposes. From this study, 25,71% are experienced with mild depression, 45,71% had moderate depression and 28,58% suffered severe depression. We propose that medicine has been rated helpful by cancer patient. Psycotherapy like music therapy is part of Complementery and Alternative Medicine (CAM) can also be considered useful in lowering negative emotions beside of routine medicine like psychopharmaceutical. Doctor and Nurse can safely recommend any of these interventions for depression.ABSTRAK Depresi merupakan masalah psikologi yang sering terjadi pada pasien kanker. Depresi dapat meningkatkan persepsi pasien akan rasa sakit, menurunkan sensitivitas khasiat pengobatan, dan memperpanjang waktu rawat di rumah sakit. Tujuan dari penelitian ini adalah untuk mengetahui gambaran kondisi depresi pada pasien kanker yang dirawat di RSUP Dr. Sardjito, Yogyakarta, dan RSUD Prof. Dr. Margono Soekarjo, Purwokerto. Ini adalah penelitian deskriptif dengan desain cross sectional dan merupakan pilot study . Total jumlah sampel adalah 70 responden. Pengambilan sampel dilakukan dengan cara non probability sampling dengan teknik purposive sampling . Alat ukur yang digunakan adalah Beck Depression Inventory (BDI). Hasil penelitian menunjukkan sebanyak 25,71% pasien kanker mengalami depresi ringan; 45,71% mengalami depresi sedang; dan 28,58% mengalami depresi berat. Saran dalam penelitian ini adalah bahwa diperlukan intervensi yang tepat untuk mengatasi gejala depresi. Selain pemberian psikofarmaka, tenaga kesehatan, khususnya dokter dan perawat, dapat memberikan psikoterapi lain, misalnya terapi musik yang merupakan bagian dari terapi komplementer
Faktor Prognostik dan Kesintasan Pasien Leukemia Limfoblastik Akut Anak di RSUP Dr. Sardjito, Yogyakarta, 2010–2015 LUSIA PUTRI WIJAYANTI; EDDY SUPRIYADI
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (500.643 KB) | DOI: 10.33371/ijoc.v11i4.532

Abstract

Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. Improvements in ALL management in developed countries have shown that the survival rate can be up to 90%. This achievement may be attributed to the stratification of therapy based on prognostic factors. This study aims to evaluate the survival rate of childhood ALL at Sardjito Hospital and prognostic factors for survival. Newly diagnosed patients with ALL aged less than 18 years from January 2010 - December 2015 were enrolled. Patients who have previously received chemotherapy, those with ALL type L3, and those with mixed leukemia were excluded. The survival rate was analyzed by Kaplan-Meier method using log-rank test. Cox regression analysis was used to identify prognostic factors. A total of 309 patients were analyzed. The survival rate of childhood LLA in 2010-2015 in Sardjito Hospital was 56.1 ± 3.9%. Risk grouping based on National Cancer Institute is a prognostic factor that influences the survival of childhood LLA. ABSTRAKLeukemia limfoblastik akut (LLA) merupakan keganasan hematologi yang paling sering ditemui pada anak. Perkembangan LLA anak di negara maju menunjukkan kesintasan pasien mencapai 90%. Keberhasilan terapi pada LLA salah satunya adalah karena adanya stratifikasi terapi berdasarkan faktor prognostik yang ada. Penelitian ini bertujuan untuk mengetahui kesintasan pasien LLA anak di RSUP Dr. Sardjito. Pasien berusia di bawah 18 tahun yang terdiagnosis LLA pada Januari 2010–Desember 2015 diikutsertakan dalam penelitian. Pasien yang pernah mendapatkan kemoterapi, LLA tipe L3, dan mixed leukemia dieksklusi. Kesintasan dianalisis dengan metode Kaplan-Meier menggunakan logrank . Analisis Cox regression digunakan untuk mengidentifikasi faktor prognostik. Sejumlah 309 pasien diikutkan dalam analisis. Kesintasan LLA anak tahun 2010–2015 di RSUP Dr. Sardjito sebesar 56,1±3,9%. Pengelompokan risiko berdasar National Cancer Institute (NCI) merupakan faktor prognostik yang berpengaruh pada kesintasan pasien LLA anak.
Perbedaan Ekspresi HBME-1 dan E-Cadherin pada Nodular Hiperplasia, Karsinoma Papiler, dan Folikular Tiroid PRIMA ROOSANDRIS; ETTY HARY KUSUMASTUTI; NILA KURNIASARI
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1225.36 KB) | DOI: 10.33371/ijoc.v11i4.530

Abstract

Thyroid lesion can be neoplastic and non neoplastic, whether benign or malignant. There are some cases in which pathologists have difficulties to differentiated those lesions. Aim: To analyze the expression of HBME-1 and E-cadherin on nodular hyperplasia, papillary carcinomas and follicular carcinomas. Paraffin blocks of nodular hyperplasia, papillary carcinoma and follicular thyroid were collected from Departement of Pathology Dr Soetomo General Hospital from January 1st, 2012 to December 31th, 2014. Immunohistochemical staining for HBME-1 and E-cadherin were performed. The difference of expression HBME-1 and E-cadherin were analyzed by Mann Whitney test, and the correlation between HBME-1 and E-cadherin determined using Spearman test. There were significant difference of HBME-1 expression between Nodular hyperplasia and Thyroid carcinoma(p≤0,05). There were also significant difference of HBME-1 between papillary and follicular carcinoma thyroid(p≤0,05). There were no significant difference of E-cadherin expression between Nodular hyperplasia and Thyroid carcinoma(p≥0,05). Conclusion: HBME-1 can be used as a marker to distinguish benign and malignant lesion of thyroid gland, and also to distinguish papillary carcinoma and follicullar carcinoma thyroid. ABSTRAK Lesi tiroid dapat berupa lesi non-neoplastik dan neoplastik, baik jinak maupun ganas. Membedakan tumor tiroid jinak dan ganas sangat penting untuk penatalaksanaan klinis yang tepat sehingga sering kali patolog menemui kesulitan dalam membedakan lesi tiroid jinak dan ganas. Penelitian ini bertujuann membuktikan adanya perbedaan ekspresi HBME-1 dan E-cadherin antara nodular hiperplasi, karsinoma papiler, dan karsinoma folikular tiroid. Dilakukan pemeriksaan imunohistokimia pada blok parafin dari nodular hiperplasia, karsinoma papiler, dan karsinoma folikular yang tersimpan di Instalasi Patologi Anatomi RSUD Dr. Soetomo (1 Januari 2012 sampai dengan 31 Desember 2014 sebanyak 35 sampel sesuai kriteria inklusi) dengan antibodi HBME-1 dan E-cadherin. Ekspresi HBME-1 dan E-cadherin dianalisis dengan uji Mann Whitney, sedangkan korelasi antara HBME-1 dan E-cadherin diuji dengan Spearman Test. Hasil penelitian menunjukkan terdapat perbedaan ekspresi HBME-1 yang signifikan antara nodular hiperplasia dan karsinoma tiroid( p≤0,05); terdapat perbedaan ekspresi HBME-1 yang signifikan antara karsinoma papiler tiroid dan karsinoma folikular tiroid (p≤0,05). Tidak terdapat perbedaan ekspresi E-cadherin yang signifikan pada nodular hiperplasi dan karsinoma tiroid (p≥0,05). Penelitian ini menyimpulkan bahwa HBME-1 dapat digunakan sebagai marker untuk mebedakan lesi jinak dan ganas kelenjar tiroid, serta dapat digunakan untuk membedakan karsinoma papiler tiroid dan karsinoma folikular tiroid.
Peran Serum IL-6 dan CA-125 Prabedah sebagai Prediktor Resektabilitas Tumor pada Kanker Ovarium Tipe Epitel ANDI KURNIADI; YUDI M HIDAYAT; DODI SUARDI; HERMAN SUSANTO; GATOT N.A.W; HERU PRAYITNO
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1245.528 KB) | DOI: 10.33371/ijoc.v11i4.533

Abstract

The success of ovarian cancer therapy is determined by optimal cytoreduction performed prior to chemotherapy. Maximum residual tumor after cytoreduction and before chemotherapy is essential for prognosis. Factors affecting tumor mass resectability are the surgeon, location of the mass, ascites more than 1000 mL, carcinomatosis, mass in lymph nodes more than 1 cm, mass at the liver parenchym, large mass up to diaphragm and pre-operative CA-125 > 500 MIU / L will increase the likelihood of suboptimal cytoreduction. IL-6 and CA-125 play a role in the occurrence of those factors, so both examinations are expected to improve the prediction of cytoreduction resectability and determine the appropriate choice for the treatment of ovarian cancer, either cytoreduction or neoadjuvant chemotherapy.The design of this study is cross sectional that is by examining patients suspected of ovarian malignancy, checking for their preoperative IL-6 and CA-125 levels and their resectability. Data analysis done by univariat and bivariate. For categorical data tested by chi-square test or Exact Fisher test, significance test used unpaired T test or Mann Whitney test. Analysis of numerical variables by numerical using Pearson correlation analysis or Spearman correlation analysis as well as correlation between numerical variables with nominal variables using Eta Correlation test. The data obtained is recorded in a special form and then processed with SPSS version 24.0 for WindowsPatients collected during the study period were 54, where only 36 people met the inclusion and exclusion criteria. It was found that most subjects were aged 40-64 years (77.8%), mean value of CA-125 for suboptimal cytoreduction group was higher than optimal cytoreduction (1099,75 + 1242,555 vs 311,23 + 160,165), which is statistically significant, p = 0,000 (p value <0,05), CA 125 cut off point in this research was 432 with sensitivity value of 72,2% and specificity value of 77,88%. The mean value of IL-6 for the suboptimal cytoreduced group was greater than the optimized cytoreduction (137.72 + 107.658 VS 62.20 + 66.330), which is statistically significant, p = 0.009 (p value <0.05), IL-6 cut off point at this study was 64.9 with a sensitivity of 72.2% and a specificity of 72.2 %. There was a positive correlation with a strong correlation strength between CA-125 levels and the operating outcome, p = 0.012 (p <0.05), there was a positive correlation with a small correlation strength between IL-6 levels and the outcome of surgery, p = 0,016 (p <0,05) and there was correlation between IL-6 and CA-125 presurgery with operating outcome (suboptimal and optimal cytoreduction) with cut off point 418,5 with sensitivity value 88.9% and specificity value 72,2% .Conclusion: There is a correlation between the levels of IL-6 and CA-125 and ovarian cancer resectability. ABSTRAKKeberhasilan terapi kanker ovarium  ditentukan oleh optimalnya sitoreduksi yang dilakukan sebelum pemberian kemoterapi. Maksimal residual tumor setelah sitoreduksi dan sebelum kemoterapi sangat penting untuk prognosis. Faktor -faktor yang mempengaruhi resektabilitas massa tumor adalah operator, lokasi massa,  asites lebih dari 1000 mL, karsinomatosis, massa di limfa lebih dari 1 cm, massa diparenkim hati, massa yang besar sampai ke diafragma dan kadar CA-125 pre-operatif > 500 mIU/L akan meningkatkan kemungkinan sitoreduksi suboptimal. IL-6 dan CA-125 berperan peran dalam terjadinya faktor – faktor tersebut, sehingga pemeriksaan kedua-duanya diharapkan dapat meningkatkan prediksi resektabilitas sitoreduksi dan menentukan pilihan tatalaksana kanker ovarium yang tepat yaitu sitoreduksi atau kemoterapi neoajuvan.Rancangan penelitian ini adalah cross sectional yaitu dengan melakukan pemeriksaan kadar IL-6 dan CA-125 prabedah  penderita tersangka keganasan ovarium kemudian dilihat resektabilitasnya.. Analisis data dilakukan secara univariat dan bivariate. Untuk data kategorik diuji dengan uji chi-square atau uji Exact Fisher , Uji kemaknaan  digunakan uji T tidak berpasangan atau uji Mann Whitney. Analisis variabel numerik dengan numerik menggunakan analisis korelasi Pearson atau analisis korelasi Spearman serta korelasi antara variabel numerik dengan variabel nominal menggunakan uji Korelasi Eta. Data yang diperoleh dicatat dalam formulir khusus kemudian diolah dengan program SPSS versi 24.0 forWindowsPasien yang berhasil dikumpulkan selama periode penelitian sebanyak 54 orang, yang memenuhi kriteria inklusi dan ekslusi hanya 36 orang. diperoleh data bahwa subjek terbanyak adalah usia 40 – 64 tahun (77,8%), Nilai rerata CA-125 untuk kelompok sitoreduksi suboptimal lebih besar dibandingkan dengan sitoreduksi optimal (1099,75 + 1242,555  VS 311,23 + 160,165 ) bermakna secara statistik     p = 0,000 (nilai p < 0,05), cut off point  CA 125 pada penelitian ini adalah 432 dengan nilai sensitivitas 72,2% dan nilai spesifisitas 77,88%. Nilai rerata IL-6 untuk kelompok sitoreduksi suboptimal lebih besar dibandingkan dengan sitoreduksi optimal (137,72 + 107,658 VS 62,20 + 66,330) bermakna secara statistik p = 0,009 (nilai p < 0,05), cut off point  IL-6 pada penelitian ini adalah 64,9 dengan  sensitivitas 72,2% dan  spesifisitas 72,2%%. Terdapat korelasi positif dengan kekuatan korelasi yang cukup kuat antara kadar CA-125 dengan luaran operasi p = 0,012 (p < 0,05), terdapat korelasi positif dengan kekuatan korelasi yang kecil (tidak erat) antara kadar IL-6 dengan luaran operasi, p = 0,016 (p < 0,05) dan terdapat korelasi antara kadar IL-6 dan CA-125 prabedah dengan luaran operasi (sitoreduksi suboptimal dan optimal ) dengan cut off point 418,5 dengan nilai sensitivitas 88.9% dan nilai spesifisitas 72,2%.Simpulan : Terdapat korelasi antara kadar IL-6 dan CA-125 prabedah dengan resektabilitas  kanker ovarium
Survei Pengetahuan Dokter Spesialis terhadap Penggunaan Opiat pada Tatalaksana Nyeri Kanker di Rumah Sakit Pemerintah, Jakarta, 2017 LENNY INDRAYANI; RIANTO SETIABUDY; VIVIAN SOETIKNO; COSPHIADY IRAWAN
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1097.236 KB) | DOI: 10.33371/ijoc.v11i4.534

Abstract

Treatment of cancer pain often requires opioids, and morphine is a gold standard in the management of severe cancer pain. Inadequate knowledge of cancer pain management causes opioid usage is not optimal. Indonesia is one of the countries with very low opioid consumption. The purpose of this study was to find out the physician’s knowledge about the management of cancer pain in choosing opioid, administration, doses, side effects, addiction and factors of opioid that barrier in pain management. This cross-sectional study was conducted in General Hospital Jakarta and a Private Hospital in Tangerang. Inclusion criteria were medical specialist who treating cancer pain. This study used questionnaires that filled out by respondents and confidential. Score of adequate knowledge was ≥ 70, and to assess the relationship between knowledge of opioid use with specialization analyzed by Chi-square test and Fisher’s exact if Chi-square requirement is not fulfilled. Statistical analysis was performed by SPSS version 20. From a total of 146 distributed questionnaires, we received 103 questionnaires (70,5%). In this study, the majority of respondents (69,9%) had inadequate knowledge. The highest rate (70,55) was found in the choosing opioid section, while the lowest rate (49,5) was found in the opioid side effects section. There is no significant relationship between physician knowledge on opioid usage and specialization (P= 0,355). Government regulation is major obstacle to opioid use, followed by lack of training, drug availability and knowledge of side effects ABSTRAK Penatalaksanaan nyeri kanker sering kali membutuhkan opiat dengan morfin sebagai gold standard menurut panduan WHO analgesic step ladder . Pengetahuan penalaksanaan nyeri kanker yang kurang menyebabkan penggunaan opiat yang tidak optimal. Indonesia merupakan salah satu negara dengan konsumsi opiat yang sangat rendah. Tujuan studi ini adalah untuk mengetahui pengetahuan dokter mengenai penanganan nyeri kanker dalam pemilihan opiat, cara pemberian, dosis, efek samping, dan adanya adiksi, serta faktor-faktor yang menjadi penghambat pada penanganan nyeri kanker. Desain penelitian ini merupakan survei potong lintang ( cross sectional ) yang dilakukan terhadap dokter spesialis yang menangani nyeri kanker di Rumah Sakit Umum Pemerintah Jakarta dan salah satu rumah sakit swasta di Tangerang. Penelitian ini menggunakan kuesioner yang diisi responden dan bersifat rahasia. Pengetahuan dianggap baik bila nilai ≥ 70. Sedangkan untuk menilai hubungan antara pengetahuan tentang penggunaan opiat dengan bidang spesialisasi dokter dianalisis dengan uji Chi-square . Hasil statistik dianalisis dengan menggunakan SPSS versi 20. Dari total 146 kuesioner yang didistribusikan, didapatkan 103 kuesioner (70,5%) yang direspons. Pada penelitian ini, mayoritas responden (69,9%) mempunyai pengetahuan yang tidak adekuat. Rerata tertinggi didapatkan pada bagian pemilihan opiat 70,55; sedangkan rerata terendah didapatkan pada bagian efek samping opiat, yaitu 47,56. Tidak terdapat hubungan bermakna antara pengetahuan dokter tentang penggunaan opiat dengan bidang spesialisasi (P= KORESPONDENSI: Lenny Indrayani Departemen Farmakologi dan Terapeutik, Universitas Indonesia. Email: lenny3ma@gmail.com Indonesian Journal of Cancer Vol. 11, No. 4 October - December 2017160 0,355). Regulasi pemerintah merupakan penghambat utama pada penggunaan opiat, disusul dengan kurangnya pelatihan, ketersediaan obat dan pengetahuan tentang efek samping.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2017 2017


Reset
Filter By Issues
All Issue Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue